Put Options

17 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2023

May 15, 2023

BUY
$15.95 - $25.18 $614,075 - $969,430
38,500 New
38,500 $718,000
Q2 2022

Aug 08, 2022

SELL
$7.94 - $12.96 $4,764 - $7,776
-600 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$12.02 - $16.79 $4,808 - $6,716
400 Added 200.0%
600 $7,000
Q4 2021

Feb 14, 2022

SELL
$9.93 - $15.39 $879,798 - $1.36 Million
-88,600 Reduced 99.77%
200 $3,000
Q3 2021

Nov 15, 2021

BUY
$10.18 - $26.64 $902,966 - $2.36 Million
88,700 Added 88700.0%
88,800 $908,000
Q2 2021

Aug 16, 2021

BUY
$18.57 - $35.68 $1,857 - $3,568
100 New
100 $3,000
Q1 2021

May 17, 2021

SELL
$31.0 - $55.72 $232,500 - $417,900
-7,500 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$37.09 - $48.97 $1.72 Million - $2.27 Million
-46,400 Reduced 86.09%
7,500 $278,000
Q3 2020

Nov 16, 2020

SELL
$40.47 - $45.5 $186,162 - $209,300
-4,600 Reduced 7.86%
53,900 $2.22 Million
Q1 2020

May 15, 2020

BUY
$23.3 - $45.96 $1.02 Million - $2.01 Million
43,800 Added 297.96%
58,500 $2.03 Million
Q4 2019

Feb 14, 2020

BUY
$34.58 - $48.06 $262,808 - $365,256
7,600 Added 107.04%
14,700 $630,000
Q3 2019

Nov 14, 2019

BUY
$36.98 - $48.45 $33,282 - $43,605
900 Added 14.52%
7,100 $263,000
Q2 2019

Aug 14, 2019

BUY
$35.13 - $55.53 $217,806 - $344,286
6,200 New
6,200 $280,000
Q4 2018

Feb 14, 2019

SELL
$37.97 - $60.16 $163,271 - $258,687
-4,300 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$56.3 - $67.25 $135,120 - $161,400
-2,400 Reduced 35.82%
4,300 $261,000
Q2 2018

Aug 14, 2018

SELL
$44.9 - $64.95 $305,320 - $441,660
-6,800 Reduced 50.37%
6,700 $419,000
Q1 2018

May 15, 2018

BUY
$45.35 - $61.65 $612,225 - $832,275
13,500 New
13,500 $624,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.